A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults
Latest Information Update: 06 Jul 2022
Price :
$35 *
At a glance
- Drugs PGDM1400 (Primary) ; PGT 121 (Primary) ; TMB-380 (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- 01 Jun 2022 Primary endpoint has been met (Antiviral activity of PGDM1400 in combination with PGT121 or PGDM1400 in combination with PGT121 and VRC07-523LS mAbs) , according to Results published in the Nature Medicine
- 01 Jun 2022 Primary endpoint has been met (Impact of viral load and/or ART) , according to Results published in the Nature Medicine
- 01 Jun 2022 Primary endpoint has been met (Area under the concentration decay curve (AUC)) , according to Results published in the Nature Medicine